S&P affirms Amgen

Standard & Poor's said it affirmed Amgen Inc.'s A+ long-term corporate credit and senior unsecured debt ratings and removed them from CreditWatch, where they were placed with negative implications on May 23 following negative sales implications for its lead drug, Aranesp. The A-1 short-term corporate credit and commercial paper ratings also were affirmed.

The outlook is now negative.

The agency said the affirmation reflects Amgen's still-strong business risk profile, despite current uncertainties with Aranesp, and continued maintenance of a very modest financial risk profile that is consistent with its current ratings.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.